Recent studies have investigated the potential of autologous bone marrow-derived mesenchymal stem cells (MSCs) as a therapy for multiple sclerosis. Whether MSCs from individuals with multiple sclerosis are functionally and/or phenotypically abnormal has received less attention. Through our Phase I clinical trial, SIAMMS, we were able to isolate and characterize MSCs from individuals with multiple sclerosis. The objective of the study was to demonstrate that MSCs from individuals with multiple sclerosis show no significant differences from MSCs derived from individuals without multiple sclerosis. MSCs were isolated from bone marrow aspirates from four SIAMMS participants. We were also able to isolate MSCs from bone marrow obtained during a total hip replacement operation on an individual with multiple sclerosis. Control MSCs were isolated from bone marrow acquired during total hip replacement operations on five individuals without MS. MSCs were characterized using standard criteria: plastic adherence, differentiation along adipogenic/osteogenic/chondrogenic lineages, and expression of specific cell surface antigens. We also determined their proliferation potential. MSCs from individuals with multiple sclerosis and individuals without multiple sclerosis were similar in proliferation, differentiation potential and cell surface antigen expression. This has relevance to scientific studies investigating the therapeutic potential of autologous MSCs which primarily utilize MSCs from individuals without multiple sclerosis, and relevance to clinical studies extrapolating from these scientific findings.
Charcot JMHistologie de la sclerose en plaques. Gazette des Hopitaux, Paris1868; 41: 554-555.
2.
Li Y., Chen J., Chen XG, et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology2002; 59: 514-523.
3.
Cogle CR, Yachnis AT, Laywell ED, et al. Bone marrow transdifferentiation in brain after transplantation: a retrospective study. Lancet2004; 363: 1432-1437.
4.
Weimann JM, Charlton CA, Brazelton TR, Hackman RC and Blau HMContribution of transplanted bone marrow cells to Purkinje neurons in human adult brains. Proc Natl Acad Sci USA2003; 100: 2088-2093.
5.
Gordon D., Pavlovska G., Glover CP, Uney JB, Wraith D. and Scolding NJHuman mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett2008; 448: 71-73.
6.
Zhang J., Li Y., Chen J., et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol2005; 195: 16-26.
7.
Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood2005; 106: 1755-1761.
8.
Bossolasco P. , Cova L., Calzarossa C., et al. Neuro-glial differentiation of human bone marrow stem cells in vitro. Exp Neurol2005; 193: 312-325.
9.
Wislet-Gendebien S., Hans G., Leprince P., Rigo JM, Moonen G. and Rogister B.Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. Stem Cells2005; 23: 392-402.
10.
Parr AM, Tator CH and Keating A.Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant2007 ; 40: 609-619.
11.
Singec I. and Snyder EYInflammation as a matchmaker: revisiting cell fusion. Nat Cell Biol2008; 10: 503-505.
12.
Uccelli A., Moretta L. and Pistoia V.Immunoregulatory function of mesenchymal stem cells. Eur J Immunol2006; 36: 2566-2573.
13.
Crigler L., Robey RC, Asawachaicharn A., Gaupp D. and Phinney DGHuman mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol2006; 198: 54-64.
14.
Wilkins A., Kemp K., Ginty M., Hares K., Mallam E. and Scolding N.Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res2009; 3: 63-70.
15.
Rice CM, Mallam EA, Whone AL, et al. Study of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. lin Pharmacol Ther2010 ; 87: 679-685.
16.
Del Papa N. , Quirici N., Soligo D., et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum2006; 54: 2605-2615.
17.
Papadaki HA , Boumpas DT, Gibson FM, et al. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol2001; 115: 167-174.
18.
Papadaki HA , Kritikos HD, Gemetzi C., et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood2002; 99: 1610-1619.
19.
Larghero J. , Farge D., Braccini A., et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis2008; 67: 443-449.
20.
Papadaki HA , Tsagournisakis M., Mastorodemos V., et al. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant2005; 36: 1053-1063.
21.
Bocelli-Tyndall C., Bracci L., Spagnoli G., et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneicstimulated lymphocytes in vitro . Rheumatology (Oxford)2007; 46: 403-408.
22.
Rice CM, Whone AL, Marks DI, Butler S., Brooks DJ and Scolding NJA safety and feasibility study of intravenous autologous bone marrow stem cells in multiple sclerosis. J Neurol Neurosurg Psych2007; 78: 1036.
23.
Greenwood SK , Hill RB, Sun JT, et al. Population doubling: a simple and more accurate estimation of cell growth suppression in the in vitro assay for chromosomal aberrations that reduces irrelevant positive results. Environ Mol Mutagen2004; 43: 36-44.
24.
Ferrero I., Mazzini L., Rustichelli D., et al. Bone marrow mesenchymal stem cells from healthy donors and sporadic amyotrophic lateral sclerosis patients. Cell Transplant2008; 17: 255-266.
25.
Dominici M. , Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy2006; 8: 315-317.
26.
Urbani S., Caporale R., Lombardini L., Bosi A. and Saccardi R.Use of CFDA-SE for evaluating the in vitro proliferation pattern of human mesenchymal stem cells. Cytotherapy2006; 8: 243-253.
27.
Mazzanti B. , Aldinucci A., Biagioli T., et al. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. J Neuroimmunol2008; 199: 142-150.
28.
Kastrinaki MC, Sidiropoulos P., Roche S., et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis . Ann Rheum Dis2008; 67: 741-749.
29.
Mareschi K. , Ferrero I., Rustichelli D., et al. Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem2006; 97: 744-754.
30.
Stenderup K., Justesen J., Clausen C. and Kassem M.Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone2003; 33: 919-926.
31.
Li J., Law HK, Lau YL and Chan GCDifferential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol2004; 127: 326-334.
32.
Lanza C., Morando S., Voci A., et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem2009 ; 110: 1674-1684.
33.
Freedman MS , Bar-Or A., Atkins HL, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis2010; 16: 503-510.
